XYA02
/ XYone Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 24, 2025
Novel MUC1-C-ADC exhibits remarkable anti-tumor potency in the treatment of triple-negative breast cancer (TNBC)
(ESMO 2025)
- "Based on these, the final ADC candidate, XYA02, was selected...Phase I clinical trials are scheduled to initiate in mid-2026. Legal entity responsible for the study Xyone Therapeutics Inc."
Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • MUC1
1 to 1
Of
1
Go to page
1